Message from the CEO IBT has announced the crucial results from the global clinical phase 3 study “The Connection Study” for our drug project...
Infant Bacterial Therapeutics AB (IBT) announces today that it has been granted a Notice of Allowance from the US Patent and Trademark Office (USPTO)...
2024-07-08 16:40
“The Connection Study” is completed
The last patient in IBT’s global phase 3 clinical program “The Connection Study” has finished treatment. IBP-9414 is being developed...
2024-05-08 18:11
Annual General Meeting of Infant Bacterial Therapeutics
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 8, 2024, among other things, the following was resolved: ContactsStaffan...
Message from the CEO IBT has successfully completed the recruitment of infants for our Phase III study (The Connection Study), which is the final clinical...
2024-04-04 19:32
Major Milestone Achieved - Last Patient Enrolled in Infant Bacterial Therapeutics’ Phase 3 Study
The last patient of 2158 premature babies has been enrolled in the global phase 3 clinical program (“The Connection Study”) for the development...
2024-04-03 11:00
Notice of Annual General Meeting of Infant Bacterial Therapeutics
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Annual General Meeting to be...
The report is available on IBT´s website, https://ibtherapeutics.com under the section Ïnvestors & Media – Financial Reports&rdquo...
2024-02-08 08:30
Infant Bacterial Therapeutics AB (publ), Interim report January 1-December 31, 2023
Message from the CEO 2023 was a very eventful year for IBT, as we pushed forward with the development of our clinical program IBP-9414 and achieved several...
2023-11-10 08:30
Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2023
Message from the CEOThe third quarter has been very eventful for IBT. In July IBT received a capital injection of 101 MSEK from our shareholders. The funds...